Institute of Biochemistry and Biotechnology




The Institute of Biochemistry and Biotechnology, affiliated to Beijing Normal University, stemmed from the Teaching and Research Room of Biochemistry established in 1958 and was officially established as the Institute of Biochemistry and Biotechnology in 2009. The Institute has a long history. Since it established the major of biochemistry in 1959 and enrolled undergraduate students in biochemistry in the same year, after half a century of evolution and accumulation, the Institute successively approved the first Master program in 1981; established the rotating post-doctoral biological posts in 1995; won the support of the key subjects construction of State Project 211 in 1996; and approved the first doctoral disciplines in 1998. The subjects of Biochemistry and Molecular Biology were classified as Beijing municipal key disciplines in 2001; the Beijing Municipal Key Laboratory of Genetic Engineering Drugs and Biotechnology was established in 2001; it became one of the "open laboratories in Zhongguancun" in the National Innovation Model area in 2009.

At present, Professor Wei Qun serves as the director of the Institute, and Professor Zhou Jie is the deputy director. There are currently twelve full-time staff, including five professors, five associate professors, two engineers, and nearly sixty Master and PhD candidates.

After years of rapid development, aiming at the development of cutting-edge biology and focusing on major practical problems in life sciences in the context of national economic development, such as human survival and health, the Institute carried out in-depth research in the aspect of both teaching and scientific research, and was awarded the second prize of National Education Outcomes Award, first prize of Beijing Education Outcomes Award, and National Advanced Courses; Science and Technology Progress Award by the Ministry of Education; six invention patents at home and abroad (including one US patent). The completed and ongoing research projects include nearly fifty programs: the "Project 863," "Project 973," the projects supported by National Natural Science Foundation of China, Major Programs, projects supported by National Science Fund for Distinguished Young Scholars, and Special Funds. More than one hundred papers were published in SCI. Currently, the Institute plays an important role in the research and teaching in these same area at home.

At present, the Institute's main research interests include:
Structure and function of biological macromolecules, including gene mutation, recombination and transformation; relationship between the protein three-dimensional structure and function; reversible phosphorylation and calcium signal transduction; protein-protein interactions; brain disorders, brain substrates and interacting proteins; the function, structure and mechanism of important enzymes and proteins in the nervous system and immune system; transgenic and plant drought resisting and salt tolerance engineering;

Bio-pharmaceutical research: research and development of anticancer drugs of innovative genetic engineering, and tumor immune mechanisms; the function of HIF and other transcription factors in cells protecting and the generating process of tumors; screening drugs via targets; herbal purification and determination of monomer structure analysis; anti-aging mechanism and drugs; research and development of nervous and immune systems drug; drugs transformation; high-throughput methods (HTS) screening for natural anti-cancer drugs.

Plant Molecular Biology: mechanism of plant light signal transduction approach, separation and function of the transcription factors such as Arabidopsis and rice, and stress tolerance of plants.

Currently the major research conducted by the Institute has taken the lead at home or abroad, and the related main products have independent intellectual property rights. The "research and development of anticancer performance of genetic engineering innovation drug CNB" has won the support of the State Drug Fund, "Project 863," Beijing Science and Technology Commission and other funds, and has turned into the industrialization development, and also won the patents of the US and China. "Alzheimer's disease pathogenesis and drugs for prevention and treatment" won the support of "Project 973" Fund of the Ministry of Science and Technology, and obtained the drug of significant role, such as ZHIERKANG capsule, which has been industrially developed, and established a fruitful cooperation with commercial enterprises. Antithrombotic drug research has received national invention patents and turned into the in-depth study stage before the transformation. In addition, taking calmodulin phosphatase as a target to establish the drug screening platform combined with the computer molecular simulation screening platform, the laboratory has selected some small molecule candidate compounds or effective intermediates, from Chinese herbal medicine, which have a role in immune regulation and anti-dementia.. Some of research on small molecule anti-aging drug also received national patent authority.

The Institute now has internationally advanced research and teaching equipment involving multiple aspects such as the biochemistry and molecular biology, bio-pharmaceuticals, plant genetic engineering and technology, as well as the opening platforms, including the required fermentation tank and chromatography system in the expression and purification of proteins; cell culture detection systems and Spot-2 image processing systems; a research platform for molecular biology and biochemistry; drug extraction and screening platform and workstation for computer simulation of SGI, etc., and is an important training base and one of the biotechnology R & D bases.




Copyright © 2011 Beijing Normal University. All rights Beijing Normal University No. 19, XinJieKouWai St., HaiDian District, Beijing 100875, P. R. China
BNU telephone directory assistance: 010-58806183 One-stop logistics service hotline: 010-58801111